Biotech Values

[rkrw]

If you consider pcop in 2 buckets, one is their own pipeline (dara, sarm), the other is all the partnered stuff (sgp and the others you listed). The lgnd ceo has said its the other bucket, the fee/royalty for service business that drove lgnd's interest. It's the internal pipeline that actually ironically was all inlicensed from bristol myers that i'm suggesting was not so impressive. You asked for an opinion :)